May 17, 2020

Is marijuana the best remedy for PMS? Foria Relief says yes

Foria Relief
Medicinal marijuana
healthcare
PMS
Admin
2 min
Foria Relief tampons contain two of the main ingredients in marijuana — THC oil and CBD.
Since the beginning of time (I'm guessing), women have been searching for the best way to relieve pain during “that time of the month.&rdquo...

Since the beginning of time (I'm guessing), women have been searching for the best way to relieve pain during “that time of the month.”

Meanwhile, people keep coming up with new ways (or at least try) to incorporate medicinal marijuana into everyday life.

RELATED TOPIC: The case for (and against) medical marijuana: A doctor's perspective

The latest product to hit the market is a tampon called Foria Relief, which contains two of the main ingredients in marijuana — THC oil and CBD — along with organic cocoa butter to assist with pain relief and instant muscle relaxation.

According to Foria, those who have used the product have reported a significant decrease in the pain and discomfort associated with menstruation. It has been carefully crafted using a delivery system intended to maximize the muscle relaxing and pain relieving properties of cannabis, without creating the psychotropic “high.”

RELATED TOPIC: Health Canada attacks marijuana advertising—Is the industry going up in smoke?

With marijuana’s long history of being a natural aide in reducing menstruation symptoms, Foria Relief intends to share its powerful medicinal properties, while utilizing modern extraction techniques to standardize purity and potency. Through this, it ensures a safe and accessible experience for all women.

Each tampon contains 60 mg of THC and 10 mg of CBD. Together, the two activate certain cannabinoid receptors in the pelvic region when introduced to the body through these specially formulated suppositories.

RELATED TOPIC: These Professors Believe Marijuana Can Defeat Antibiotic-Resistant Bacteria

These cannabinoids directly affect the immune system and the nerve endings of the uterus, cervix, ovaries and surrounding smooth muscle tissues. In addition, the THC assists in blocking out pain and allows more pleasant signals to be received by the brain, while CBD works in the immune system by suppressing the mechanisms responsible for inflammation.

“We are committed to promoting good health and well-being, especially with respect to people’s experience of intimacy, by creating products that enhance natural, sensual pleasures and provide relief from discomfort and pain,” says Foria’s mission statement. “Foria harnesses the complex powers of cannabis to create potent ‘therapeutic aphrodisiacs’ and healing products, thoughtfully designed for both women and men.”

RELATED TOPIC: Australian economy looks for lift from medical marijuana

The tampons are currently only available in California and Colorado, where marijuana is legal.

Source: Women’s Health

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article